Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform
Open Access
- 21 April 2016
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (7) , e1171446
Abstract
Background: Anticancer vaccines could represent a valuable complementary strategy to established therapies, especially in settings of early stage and minimal residual disease. HER-2 is an important target for immunotherapy and addressed by the monoclonal antibody trastuzumab. We have previously generated HER-2 mimotope peptides from phage display libraries. The synthesized peptides were coupled to carriers and applied for epitope-specific induction of trastuzumab-like IgG. For simplification and to avoid methodological limitations of synthesis and coupling chemistry, we herewith present a novel and optimized approach by using adeno-associated viruses (AAV) as effective and high-density mimotope-display system, which can be directly used for vaccination. Methods: An AAV capsid display library was constructed by genetically incorporating random peptides in a plasmid encoding the wild-type AAV2 capsid protein. AAV clones, expressing peptides specifically reactive to trastuzumab, were employed to immunize BALB/c mice. Antibody titers against human HER-2 were determined, and the isotype composition and functional properties of these were tested. Finally, prophylactically immunized mice were challenged with human HER-2 transfected mouse D2F2/E2 cells. Results: HER-2 mimotope AAV-vaccines induced antibodies specific to human HER-2. Two clones were selected for immunization of mice, which were subsequently grafted D2F2/E2 cells. Both mimotope AAV clones delayed the growth of tumors significantly, as compared to controls. Conclusion: In this study, a novel mimotope AAV-based platform was created allowing the isolation of mimotopes, which can be directly used as anticancer vaccines. The example of trastuzumab AAV-mimotopes demonstrates that this vaccine strategy could help to establish active immunotherapy for breast-cancer patients.Keywords
This publication has 68 references indexed in Scilit:
- Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine CandidatePLOS ONE, 2012
- The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Mimotope vaccination – from allergy to cancerExpert Opinion on Biological Therapy, 2009
- Gene Therapy Using Adeno-Associated Virus VectorsClinical Microbiology Reviews, 2008
- Genetically Programmed Biases in Th1 and Th2 Immune Responses Modulate AtherogenesisThe American Journal of Pathology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Mimotope vaccines: Epitope mimics induce anti-cancer antibodiesImmunology Letters, 2007
- Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytesJournal of Molecular and Cellular Cardiology, 2006
- Lessons from Coley's ToxinSurgical Oncology, 2006
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003